Literature DB >> 25809059

The Implementation of the Bethesda System for Reporting Thyroid Cytopathology Improves Malignancy Detection Despite Lower Rate of Thyroidectomy in Indeterminate Nodules.

Dania Hirsch1, Eyal Robenshtok, Gideon Bachar, Diana Braslavsky, Carlos Benbassat.   

Abstract

BACKGROUND: The Bethesda system for reporting thyroid cytopathology (TBSRTC) was developed in 2009 to standardize the terminology for interpreting fine-needle aspiration (FNA) specimens.
METHODS: A historical prospective case series design was employed. The study group included patients with a thyroid nodule classified as TBSRTC AUS/FLUS (B3) or FN/SFN (B4) in 2011-2012 in a tertiary university-affiliated medical center. Rates of surgery and malignancy detection were compared to our pre-TBSRTC (1999-2000) study.
RESULTS: Of 3927 nodules aspirated, 575 (14.6%) were categorized as B3/B4. Complete data were available for 322. Thyroidectomy was performed in 123 (38.2%) cases: 66/250 (26.4%) B3 and 57/72 (79.2%) B4. Differentiated thyroid cancer was found in 66 (53.7%) patients: 30/66 (45.5%) B3 and 36/57 (63.2%) B4 (p=0.075). Operated patients were younger than the non-operated (B3: 52.4±16 vs. 59.7±13 years, p=0.009; B4: 51.7±15 vs. 60.5±14 years, p=0.042), and operated B3 nodules were larger than the non-operated (27.2 vs. 22.2 mm, p=0.014). Additional FNA was done in 160 patients (49.7%): 137/250 (54.8%) B3 and 23/72 (31.9%) B4 (p=0.002). The additional B3 nodules aspirations yielded a diagnosis of B2 in 84 patients (61.3%), B3 in 48 (35%), and B4 in 5 (3.6%). Of the 23 repeated B4 aspirations, B2 was reported in 5 (21.7%), B3 in 12 (52.2%), B4 in 4 (17.4%), and B6 in 2 (8.7%). The number of aspirated nodules was twice that reported in 1999-2000. The rate of indeterminate nodules increased from 6 to 14.6%, the surgery rate decreased from 52.3 to 38.2%, and the accuracy of malignancy diagnosis increased from 25.9 to 53.7%.
CONCLUSIONS: The application of TBSRTC significantly improves diagnostic accuracy for indeterminate thyroid nodules, leading to higher rates of malignancy detection despite lower rates of thyroidectomies.

Entities:  

Mesh:

Year:  2015        PMID: 25809059     DOI: 10.1007/s00268-015-3032-6

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  37 in total

1.  Diagnostic accuracy of surgeon-performed ultrasound-guided fine-needle aspiration of thyroid nodules.

Authors:  Linda Bohacek; Mira Milas; Jamie Mitchell; Allan Siperstein; Eren Berber
Journal:  Ann Surg Oncol       Date:  2011-06-02       Impact factor: 5.344

2.  Evaluation of the thyroid nodule.

Authors:  Bryan McIver
Journal:  Oral Oncol       Date:  2013-05-23       Impact factor: 5.337

3.  Thyroid fine-needle aspiration reporting rates and outcomes before and after Bethesda implementation within a combined academic and community hospital system.

Authors:  Aaron M Harvey; Dina R Mody; Mojgan Amrikachi
Journal:  Arch Pathol Lab Med       Date:  2013-11       Impact factor: 5.534

4.  Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer.

Authors:  David S Cooper; Gerard M Doherty; Bryan R Haugen; Bryan R Hauger; Richard T Kloos; Stephanie L Lee; Susan J Mandel; Ernest L Mazzaferri; Bryan McIver; Furio Pacini; Martin Schlumberger; Steven I Sherman; David L Steward; R Michael Tuttle
Journal:  Thyroid       Date:  2009-11       Impact factor: 6.568

5.  Thyroid palpation versus high-resolution thyroid ultrasonography in the detection of nodules.

Authors:  P W Wiest; M F Hartshorne; P D Inskip; L A Crooks; B S Vela; R J Telepak; M R Williamson; R Blumhardt; J M Bauman; M Tekkel
Journal:  J Ultrasound Med       Date:  1998-08       Impact factor: 2.153

6.  The Bethesda thyroid fine-needle aspiration classification system: year 1 at an academic institution.

Authors:  Constantine G A Theoharis; Kevin M Schofield; Lynwood Hammers; Robert Udelsman; David C Chhieng
Journal:  Thyroid       Date:  2009-11       Impact factor: 6.568

7.  Preoperative diagnosis of benign thyroid nodules with indeterminate cytology.

Authors:  Erik K Alexander; Giulia C Kennedy; Zubair W Baloch; Edmund S Cibas; Darya Chudova; James Diggans; Lyssa Friedman; Richard T Kloos; Virginia A LiVolsi; Susan J Mandel; Stephen S Raab; Juan Rosai; David L Steward; P Sean Walsh; Jonathan I Wilde; Martha A Zeiger; Richard B Lanman; Bryan R Haugen
Journal:  N Engl J Med       Date:  2012-06-25       Impact factor: 91.245

8.  A single institution experience with the new bethesda system for reporting thyroid cytopathology: correlation with existing cytologic, clinical, and histological data.

Authors:  Michele K McElroy; Sepi Mahooti; Farnaz Hasteh
Journal:  Diagn Cytopathol       Date:  2014-01-16       Impact factor: 1.582

9.  Effect of the Bethesda system for reporting thyroid cytopathology on thyroidectomy rates and malignancy risk in cytologically indeterminate lesions.

Authors:  Jennifer L Rabaglia; Wareef Kabbani; Lucy Wallace; Shelby Holt; Lori Watumull; Jeffrey Pruitt; William H Snyder; Fiemu E Nwariaku
Journal:  Surgery       Date:  2010-12       Impact factor: 3.982

10.  Malignancy rate in thyroid nodules classified as Bethesda category III (AUS/FLUS).

Authors:  Allen S Ho; Evan E Sarti; Kunal S Jain; Hangjun Wang; Iain J Nixon; Ashok R Shaha; Jatin P Shah; Dennis H Kraus; Ronald Ghossein; Stephanie A Fish; Richard J Wong; Oscar Lin; Luc G T Morris
Journal:  Thyroid       Date:  2014-03-10       Impact factor: 6.568

View more
  7 in total

1.  Gene expression classifier for the diagnosis of indeterminate thyroid nodules: a meta-analysis.

Authors:  Prasanna Santhanam; Rodhan Khthir; Todd Gress; Ayman Elkadry; Omolola Olajide; Abid Yaqub; Henry Driscoll
Journal:  Med Oncol       Date:  2016-01-09       Impact factor: 3.064

2.  Bethesda Categorization of Thyroid Nodule Cytology and Prediction of Thyroid Cancer Type and Prognosis.

Authors:  Xiaoyun Liu; Marco Medici; Norra Kwong; Trevor E Angell; Ellen Marqusee; Matthew I Kim; P Reed Larsen; Nancy L Cho; Matthew A Nehs; Daniel T Ruan; Atul Gawande; Francis Moore; Justine Barletta; Jeffrey F Krane; Edmund S Cibas; Tao Yang; Erik K Alexander
Journal:  Thyroid       Date:  2015-12-16       Impact factor: 6.568

3.  Validating the 'CUT score' risk stratification tool for indeterminate thyroid nodules using the Bethesda system for reporting thyroid cytopathology.

Authors:  Sapir Pinhas; Idit Tessler; Luba Pasherstnik Bizer; Khaled Khalilia; Meir Warman; Meital Adi; Doron Halperin; Oded Cohen
Journal:  Eur Arch Otorhinolaryngol       Date:  2021-04-12       Impact factor: 2.503

4.  Adherence to Active Surveillance and Clinical Outcomes in Patients with Indeterminate Thyroid Nodules Not Referred for Thyroidectomy.

Authors:  Alexander Gorshtein; Ilana Slutzky-Shraga; Eyal Robenshtok; Carlos Benbassat; Dania Hirsch
Journal:  Eur Thyroid J       Date:  2020-08-06

5.  Multimodality Molecular Imaging (FDG-PET/CT, US Elastography, and DWI-MRI) as Complimentary Adjunct for Enhancing Diagnostic Confidence in Reported Intermediate Risk Category Thyroid Nodules on Bethesda Thyroid Cytopathology Reporting System.

Authors:  Sandip Basu; Abhishek Mahajan; Supreeta Arya
Journal:  World J Nucl Med       Date:  2016 May-Aug

6.  The Diagnostic Performance of Thyroid US in Each Category of the Bethesda System for Reporting Thyroid Cytopathology.

Authors:  So Yoon Park; Soo Yeon Hahn; Jung Hee Shin; Eun Young Ko; Young Lyun Oh
Journal:  PLoS One       Date:  2016-06-27       Impact factor: 3.240

7.  Thyroid Bethesda Category AUS/FLUS in Our Microscopes: Three-Year-Experience and Cyto-Histological Correlation.

Authors:  Roope Huhtamella; Ivana Kholová
Journal:  Cancers (Basel)       Date:  2019-10-28       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.